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Abstract
Background: Pulmonary lymphangioleiomyomatosis (LAM) is a rare disease of women characterized by multiple
lung cysts leading to respiratory insufficiency and frequent pneumothorax (PT). Air travel (AT) could increase the risk
of PT in LAM through rupture of subpleural cysts induced by atmospheric pressure changes in aircraft cabin. To
determine whether AT increases the risk of PT in LAM, we performed a retrospective survey of members of European
LAM patient associations. A flight-related PT was defined as occurring ≤30 days after AT.
Results: 145 women reported 207 PT. In 128 patients with available data, the annual incidence of PT was 8% since the
first symptoms of LAM and 5% since LAM diagnosis, compared to 0.006% in the general female population. Following
surgical or chemical pleurodesis, the probability of remaining free of PT recurrence was respectively 82, 68, and 59%
after 1, 5 and 10 years, as compared to only 55, 46 and 39% without pleurodesis (p = 0.026). 70 patients with available
data performed 178 AT. 6 flight-related PT occurred in 5 patients. PT incidence since first symptoms of LAM was
significantly higher ≤30 days after AT as compared to non-flight periods (22 versus 6%, risk ratio 3.58, confidence
interval 1.40–7.45).
Conclusions: The incidence of PT in LAM is about 1000 times higher than in the general female population, and is
further increased threefold after AT. Chemical or surgical pleurodesis partly reduces the risk of PT recurrence in LAM.
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Background
Pulmonary lymphangioleiomyomatosis (LAM) is a rare
disease affecting almost exclusively women in their re-
productive age. It is characterised by the proliferation of
abnormal smooth muscle-like cells (LAM cells) in the
lungs and lymphatic system, and is considered as a
low-grade metastasizing neoplasm [1–5]. In the lungs,
LAM cell proliferation leads to the development of mul-
tiple thin-walled cysts and progressive destruction of the
parenchyma resulting in dyspnea, obstructive ventilatory
defect, reduced carbon monoxide transfer factor, and
hypoxemia [6–10]. Another typical feature of pulmonary
LAM is the occurrence of pneumothorax (PT), which
affects more than half of patients during disease course
with frequent relapses [6–9].
Air travel (AT) is a matter of concern in patients with
LAM [11]. During commercial flights, the cruising alti-
tude varies between 4′534 and 14′630 m, and aircraft
cabin is pressurized to approximately 565 mmHg corre-
sponding to an altitude of 2438m. The resulting
decrease in alveolar oxygen partial pressure may worsen
pre-existing hypoxemia in patients with respiratory dis-
eases. In addition, following Boyle’s law, when baromet-
ric pressure decreases during ascent, the air eventually
trapped in a non-communicating space such as a pul-
monary cyst may increase its initial volume by 30%, and
could lead to overinflation and rupture, with consecutive
PT [12–14]. The occurrence of a PT during flight may
have serious consequences in patients with impaired
lung function, and its treatment in such circumstances
may be delayed. In 2 retrospective studies addressing the
issue of AT in patients with LAM, the reported fre-
quency of PT after AT was respectively 2.2 and 1.1% per
flight [11, 15]. However, these studies did not determine
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whether AT by itself constitutes a risk factor for the oc-
currence of PT.
To explore this issue, we performed a survey of Euro-
pean LAM patients. The main objectives were to calculate
the annual incidence rate of PT in LAM, and to determine
whether AT increases the risk of PT in this population.
Methods
Patient recruitment
Patients with pulmonary LAM were recruited through
European LAM patient associations in France, Germany,
Italy, Spain, United Kingdom, and a rare lung disease
registry in Switzerland. Isolated patients from other
countries were also recruited on an individual basis.
Data were collected retrospectively through a question-
naire available in the local language. Patients provided
informed consent.
Data collection
Patients were asked to provide detailed information re-
garding the date of first symptoms attributable to LAM,
date of LAM diagnosis, current forced expiratory vol-
ume in one second (FEV1) if known, and the occurrence
and date of lung transplantation. They were also asked
to report details on each episode of PT, which occurred
since the first symptoms of LAM, including date of PT,
affected side, and treatment received according to
pre-specified categories (spontaneous resolution, needle
aspiration, chest tube, or chemical or surgical pleurod-
esis). Patients were also asked to report with the best
possible accuracy the first 4 AT which took place since
the first symptoms of LAM, including date, origin and
destination, occurrence of PT during or after AT, and
whether it occurred on a lung previously treated for PT.
Patients were encouraged to provide dates with the best
possible accuracy from personal archives (diaries, travel
invoices), and obtain details on PT dates and treatments
from their physician. The French patient association
France Lymphangioléiomyomatose (FLAM) performed
data collection and capture. An anonymized database
was provided to the investigators. Patients who were
identified by the survey as experiencing a PT ≤ 30 days
after AT received a second questionnaire to ascertain
that PT was diagnosed by a physician and by chest
X-ray, the dates of AT and PT, and the treatments
received.
Data analysis
In a first set of analyses, we determined the overall inci-
dence of PT in the study population. The beginning of
exposure to the risk of PT was defined as the date of the
first symptoms attributable to LAM, and in a second
analysis as the date of LAM diagnosis. The end of ex-
posure to the risk of PT was defined as the date of
survey completion. When a PT was the first symptom
attributable to LAM, it was included in the calculation
of PT incidence during the exposure period, which
started with the first symptom. We considered 2 differ-
ent hypotheses to compute PT incidence: 1) the risk of
PT is constant across the whole LAM population, 2) the
risk of PT is variable from one patient to another. A
standard Poisson regression (model 1) was used to com-
pute the incidence according to the first hypothesis. To
compute PT incidence according to the second hypoth-
esis, we used 2 different regression models to estimate
the variable risk [16]: a negative binomial regression
(model 2), and a Poisson regression with a random inter-
cept (model 3). In each of these models, only an inter-
cept was considered (mean model). Model 1 is
equivalent to calculate the ratio of the total number of
observed PT and the sum of all exposure periods. In
model 2, we hypothesized that the incidence was distrib-
uted as a gamma distribution (the negative binomial dis-
tribution can be viewed as a Poisson distribution where
the parameter is itself a random variable distributed as a
gamma distribution). In this model, the estimation of
the intercept leads to an estimation of the mean inci-
dence rate (over the patients). In model 3, we supposed
that the intercept was normally distributed and therefore
the incidence followed a log-normal distribution. In this
model, the estimation of the intercept leads to an esti-
mation of the median incidence rate. Patients were with-
drawn from the analysis if the date of the first
symptoms, the date of LAM diagnosis, or any date of
PT were missing. Transplanted lungs were not consid-
ered at higher risk for PT and were withdraw from the
calculation.
In a second set of analyses, we determined whether
pleurodesis reduced the risk of PT in the study popula-
tion. For this purpose, we compared the recurrence rate
of PT after conservative treatment (spontaneous reso-
lution, needle aspiration or chest tube) and after medical
or surgical pleurodesis in patients who experienced a
first episode of PT, using the Kaplan-Meier method.
Each lung was considered as an independent observa-
tion. Patients were withdrawn from the analysis if any
date of PT or the affected side were missing, or if they
never experienced a PT.
In a third set of analyses, we determined whether AT
increased the risk of PT occurrence in LAM. A PT was
arbitrarily defined as related to AT if it was diagnosed by
chest X-ray within 30 days after AT. This time interval
was defined before the survey. Although cyst rupture re-
lated to barometric pressure change is expected to occur
during AT, the resulting PT (i.e. the leak of a significant
amount of air from the airspaces to the pleural cavity
through the ruptured cyst) may be delayed, as suggested
for another cystic lung disease, the Birth-Hogg-Dubé
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syndrome (BHD) [17]. An interval of up to 30 days has
also been observed in a study on the occurrence of PT
due to AT in BHD [18]. We also considered that a
patient with mild respiratory symptoms may have seeked
medical attention only after several days.
Each lung was considered as an independent observa-
tion. Patients were withdrawn from the analyses if any
date of PT, the affected side, or any date of AT were
missing. Based on our (see below) and previous findings
[19] that pleurodesis was only moderately effective in
reducing the risk of PT recurrence, lungs treated with
pleurodesis were still considered at risk of PT.
An AT was defined as both an outbound and a return
trip, each of which may have consisted of one or more
stops, i.e. one or more episodes of ascent and descent.
The time interval between outbound and return trips
was not recorded, but we reasoned that in the vast ma-
jority of AT, the duration of a trip would be < 15 days.
Indeed, according to European statistics, the average
duration of trips performed by European citizen is 5.4
days [20], and 94% of trips last < 14 days [21]. Thus, the
interval of 30 days after the outbound trip was consid-
ered appropriate to observe the occurrence of PT related
to an AT. The date of AT, defined as the date of the first
outbound flight, was considered as day 0.
To determine whether AT increased the risk of PT
occurrence, we compared the incidence of PT during
the 30 days following AT (days 0 to + 29) to the inci-
dence of PT at all other periods, i.e. before AT (from
first symptoms or diagnosis) and > 30 days after AT. A
standard Poisson regression was used for these analyses.
Quantitative data were expressed as mean and standard
deviation (SD). Statistical analyses were performed with
the R software version 3.4.4 [22].
Results
Study population
145 filled questionnaires were available. All patients were
women. Their countries of origin were France (31.7%),
Germany (23.4%), United Kingdom (17.2%), Italy
(15.2%), Spain (5.5%), Switzerland (4.1%), Austria (0.7%),
Belgium (0.7%), Ireland (0.7%), and Turkey (0.7%). The
response rate, available for the French association, was
51%. The mean (SD) age at time of survey was 47 (12)
years. The mean (SD) age was 36 (11) years at first
symptoms attributable to LAM (n = 139), and 41
(11) years at LAM diagnosis (n = 145). The mean (SD)
FEV1 at time of survey was 58 (24) % predicted (n = 71).
Incidence of pneumothorax in LAM
Among the 145 patients, 6 had missing dates of first
symptoms of LAM, and 11 had one or more dates of PT
missing. In the remaining 128 patients, the mean
follow-up duration since the first symptoms attributable
to LAM was 11.4 years, and the cumulated follow-up
duration was 1454 patient-years. The mean follow-up
duration since LAM diagnosis was 6.4 years, with a cu-
mulated follow-up duration of 817 patient-years.
The 145 patients reported a total of 207 PT.
Eighty-three patients (57%) had at least one PT, and 56
(39%) had 2 or more PT. Among the 137 patients for
whom the side of each PT was determined, the mean
(SD) number of PT per lung was 1.8 (1.0).
In the 128 patients with available data, the annual inci-
dence rate of PT since the first symptoms of LAM and
since LAM diagnosis according to the 3 statistical
models are shown in Table 1. Since the number of PT
varied widely among patients, we considered that model
3 was the most appropriate to describe the incidence of
PT. With this model, the annual incidence of PT was 8%
since first symptoms of LAM, and 5% since LAM diag-
nosis. Higher rates were found with the 2 other statis-
tical models (Table 1), showing that model 3 was the
most conservative.
Efficacy of pleurodesis to prevent recurrence of PT
The probability of remaining free of PT recurrence with-
out pleurodesis was 55% at one year, 46% at 5 years and
39% at 10 years after the initial PT, versus 82, 68 and
59% with pleurodesis, respectively (p = 0.026, Log rank,
Kaplan-Meier method) (Fig. 1). No significant difference
was observed between chemical and surgical pleurodesis
(p = 0.69, data not shown). As the protective effect of
pleurodesis was only partial, and for the purpose of cal-
culating the risk of PT after AT, we considered that a
lung treated with pleurodesis remained at risk of PT
afterwards.
Risk of pneumothorax after air travel
Eighty-three out of 145 patients (57%) travelled by air.
Among them, 3 (cases 26, 36, and 79) had missing or in-
complete dates of AT, 3 (cases 38, 53, and 89) had
Table 1 Annual incidence rate of pneumothorax in LAM (n = 128)
Start of exposure period Model 1 Model 2 Model 3
First symptoms of LAM 0.12 (0.1, 0.14) 0.18 (0.13, 0.24) 0.08 (0.05, 0.11)
LAM diagnosis 0.09 (0.07, 0.11) 0.11 (0.07, 0.15) 0.05 (0.03, 0.08)
Data were calculated from 3 models: Model 1: constant risk of PT across the whole LAM population, standard Poisson regression. Model 2: variable risk from one
patient to another, negative binomial regression. Model 3: variable risk from one patient to another, Poisson regression with random intercept. Results are
expressed as incidence per patient per year (95% confidence intervals)
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missing or incomplete dates of PT, and 4 (cases 11, 38,
89, and 93) had missing side of PT. In one other patient
(case 141), a PT was reported on the same day as an AT,
but this event was not counted since all AT (n = 3) and
PT (n = 4) in this patient were reported as occurring on
January 1st, which was considered very unlikely. More-
over, 4 patients had missing dates of first symptoms of
LAM or did not fly after first symptoms of LAM (cases
31, 75, 97, 144). Thus, after removing these 13 cases, a
population of 70 patients was used to determine the risk
of PT associated with AT after the first symptoms of
LAM. These 70 patients reported a total of 178 AT.
Considering each lung as an independent observation,
140 lungs performed a total of 356 AT. After LAM diag-
nosis, 57 patients performed 139 AT, or 114 lungs per-
formed 278 AT.
Six PT occurred in 5 patients (bilateral PT in one
patient revealing the disease) within 30 days after AT
(Table 2), including 4 patients who experienced their
first PT at this occasion, and one who had 3 PT pre-
viously and relapsed on the same side despite previ-
ous chemical pleurodesis. Three other patients (cases
27, 98, and 107) mentioned the occurrence of PT
after AT in comments, but since this was not consist-
ent with the reported dates of PT and AT, these nar-
ratively mentioned PT were not counted. Overall, the
rate of PT within 30 days after AT was 2.8% (5/178)
per patient and 1.7% (6/356) per lung after first
symptoms of LAM. After LAM diagnosis, the rate of
PT within 30 days after AT was 2.2% (3/139) per
patient and 1.1% (3/278) per lung.
The incidence of PT within 30 days after AT was com-
pared to the incidence of PT during all non-flight pe-
riods since first symptoms of LAM, and since LAM
diagnosis, respectively (Table 3). When using the first
symptoms of LAM as the beginning of the period at risk,
a significantly higher incidence of PT was found within
30 days after AT (0.223, CI 0.089–0.453) as compared to
non-flight periods (0.062, CI 0.052–0.075) with a risk ra-
tio of 3.58 (CI 1.40–7.45). When using the date of LAM
diagnosis as the beginning of the period at risk, the inci-
dence of PT was also increased within 30 days after AT
(0.143, CI 0.035–0.370) as compared to non-flight pe-
riods (0.044, CI 0.032–0.059), but the difference did not
reach statistical significance (risk ratio 3.25, CI 0.79–
8.93). No PT was counted twice because of overlapping
periods at risk.
Discussion
In the present study, we determined for the first time
the incidence of PT in LAM, which is about 1000 times
higher than in the general women population. Another
new finding is that the incidence of PT is increased
threefold after AT compared to baseline incidence, sug-
gesting that AT could be a risk factor for the occurrence
of PT in LAM. Additionally, we confirm previous data
showing that pleurodesis is partly effective in reducing
the recurrence rate of PT in LAM [19].
Fig. 1 Probability of pneumothorax-free course after the first pneumothorax, according to treatment received for this pneumothorax. Each lung
was considered as a separate observation. Probability of pneumothorax-free course was significantly lower after conservative treatment (C, grey
solid line) than after chemical or surgical pleurodesis (P, black broken line) (p = 0.026, log-rank test). Grey areas reflect 5–95% confidence intervals.
Data were censored at the date of questionnaire filling if a second pneumothorax did not occur. PT: pneumothorax
Gonano et al. Orphanet Journal of Rare Diseases          (2018) 13:222 Page 4 of 8
Several series have reported that 50 to 80% of LAM
patients experience PT during disease course [6–9], but
the incidence of PT in LAM has not been determined
previously. Based on the wide interindividual variation
in the number of PT observed in the present study
(range 0–4), we considered that the risk of PT would be
variable from one patient to another, and as the median
is more robust to outliers than the mean, model 3 was
considered the most appropriate. With this model, the
incidence of PT in the LAM population was 8% per year
from the first symptoms of LAM, and 5% per year from
LAM diagnosis. In comparison, the incidence of
spontaneous PT in the general female population is 1 to
6/100′000 per year, or 0.001 to 0.006% [23]. Using the
most conservative estimate, the incidence of PT in LAM
is therefore about 1000 times higher than in the general
population.
Only one retrospective survey has previously examined
the efficacy of pleurodesis to prevent PT recurrence in
LAM [19]. Among 301 episodes of first PT in 193
patients, the recurrence rate was 66% after conservative
therapy, 27% after chemical pleurodesis and 32% after
surgical pleurodesis [19]. In the present study, we con-
firm that pleurodesis significantly reduces the risk of PT
recurrence in LAM (Fig. 1), and that chemical and surgi-
cal pleurodesis are of similar efficacy. However, the risk
of recurrence after pleurodesis remained much higher
than in spontaneous primary PT, with reported recur-
rence rates of 0 to 3.2% after surgical pleurodesis, and
2.5 to 10% after thoracoscopic talc poudrage [24]. Based
on these findings, we considered that LAM patients with
pleurodesis remain at risk of PT after AT, and did not
exclude post-pleurodesis periods from calculations. In-
deed, among the 5 patients who had a PT within 30 days
after AT, one had a previous pleurodesis on the same
side.
The incidence of PT during AT aboard commercial
aircrafts in the general population is unknown but prob-
ably very low. Only 0.003% of passengers have an
in-flight medical problem requiring emergency interven-
tion [25], and PT is usually not mentioned in studies on
in-flight emergencies [25–27]. However, there are several
case reports of in-flight PT [14, 25, 28–30]. Further-
more, a relationship between atmospheric pressure
changes and occurrence of spontaneous PT has been
demonstrated in several studies [31–34]. A case of spon-
taneous PT triggered by an ascent of 350 m in a
high-speed lift has also been reported [35]. In the US
Air Force personnel, the incidence of spontaneous PT
was 47/100′000/year [36], i.e. fourfold higher than in the
US Navy [36] or the general male population [23]. Taken
together, these data suggest that variations of atmos-
pheric pressure during AT may trigger PT. Although the
risk appears very low in the general population, it may
be higher in subjects prone to PT, such as LAM patients.
Lung function testing has also been shown to trigger PT
in LAM patients with an incidence rate of 0.02 to 0.04/
100 tests [37], which is certainly much higher than in
Table 2 Characteristics of LAM patients who presented PT within 30 days after AT
Case
number
Age at PT
(years)
Number of previous
PT
Side of current
PT
Delay between AT and PT
(days)
Perceived relationship
between AT and PT
PT treatment
143 26 0 R 0 yes surgical pleurodesis
143 26 0 L 0 yes surgical pleurodesis
84 64 0 R 19 yes chemical
pleurodesis
25 26 0 L 24 yes surgical pleurodesis
102 44 3 R 29 no spontaneous
healing
142 59 0 R 29 yes surgical pleurodesis
PT Pneumothorax, AT air travel, L Left, R Right
Table 3 Incidence of PT during post-flight and non-flight periods
Start of exposure
period
Exposure period
type
Exposure period duration
(lung-yr)
Number of PT during
exposure period
PT incidence per lung
per yr (CI)
Risk ratio (CI)
first symptoms of LAM total 1835.4 119 0.065 (0.054–0.077)
non-flight 1808.6 113 0.062 (0.052–0.075)
3.58 (1.40–7.45)
30 days post-flight 26.8 6 0.223 (0.089–0.453)
LAM diagnosis total 930.7 43 0.046 (0.034–0.061)
non-flight 909.7 40 0.044 (0.032–0.059)
3.25 (0.79–8.93)
30 days post-flight 21.0 3 0.143 (0.035–0.370)
CI confidence interval
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the general population. To our knowledge, despite the
extremely wide use of this procedure, only 3 cases of PT
after lung function testing have been reported in the lit-
erature [38–40].
Two previous studies have analysed the occurrence of
PT related to AT in LAM patients [11, 15]. The first
study surveyed members of the LAM Foundation (USA)
and the LAM Action registry (UK) who travelled by air.
The rate of PT was estimated to 4% per patient and
2.2% per flight [11]. In another study of LAM patients
who travelled to the National Institutes of Health, the
rate of PT related to AT was 2.9% per patient and 1.1%
per flight, compared to 1.3% per patient and 0.5% per
journey with ground travel [15]. The rate of PT in the
present study (2.8% per patient per flight and 1.7% per
lung per flight) is consistent with these previous findings
[11, 15], thus reinforcing the validity of our observations.
However, these previous studies did not provide any in-
formation on a possible causal relationship between AT
and PT because no comparison was made between
patients who flew and those who did not fly [11, 15].
In contrast, and for the first time, we compared the
incidence of PT after AT with the baseline incidence
of PT in LAM, to assess the risk of PT attributable
to AT. We observed a significant threefold increase of
PT incidence ≤30 days after AT as compared to
non-flight periods (22 versus 6% per year, risk ratio
3.58, CI 1.40–7.45) when using the date of first symp-
toms as the beginning of the period at risk. A similar
threefold increase was observed when the period at
risk was calculated from the date of diagnosis (14 ver-
sus 4% per year, risk ratio 3.25, CI 0.79–8.93), al-
though the difference did not reach statistical
significance due to a smaller sample size. We however
believe that the date of first symptoms is more rele-
vant than the date of diagnosis to define the period a
risk in LAM, since PT is the first disease manifest-
ation in about half of cases, and diagnosis is often de-
layed by several years [6, 7]. Indeed, in the present
study, the mean age at first symptoms was 36 years,
whereas the mean age at diagnosis was 41 years. Dis-
carding the period between first symptoms and diag-
nosis would have led to miss a time span during
which patients are already exposed to the risk of PT,
as well as a significant proportion of events. Indeed,
among the 5 patients who experienced PT after AT,
one had bilateral PT after AT as the first disease
manifestation. Altogether, our findings suggest for the
first time that AT by itself could be a risk factor for
PT occurrence in LAM.
The 2010 European Respiratory Society guidelines on
LAM provided recommendations regarding AT [41].
LAM patients with minimal respiratory manifestations
were not discouraged to fly, unless they presented new
respiratory symptoms not evaluated by a physician. Pa-
tients with a known untreated PT or a PT treated within
the previous month were advised not to travel by air.
We believe that our findings should not lead to modify
these recommendations, as the additional risk of AT is
much smaller than the baseline risk of PT in LAM.
However, patients should be informed of this additional
risk.
Recently, Johannesma et al. evaluated by question-
naires the risk of spontaneous PT due to AT in patients
with BHD, an autosomal genetic disease characterised
by skin lesions, renal tumors and multiple pulmonary
cysts [11, 15, 18]. From the 145 patients who flew, 13
presented a PT confirmed by chest X-ray ≤1 month after
AT. The risk was 0.63% per flight, i.e. lower than in
LAM (11, 15, 18, and the present study). Consistently,
the frequency of PT during disease course is lower in
BHD (35–38%) than in LAM (50–80%) [6–9, 19, 37, 42,
43], a difference possibly explained by less numerous
cysts in BHD, or cysts less prone to rupture [18].
The present study has several strengths. We studied
a relatively large cohort of patients with LAM from
various countries. We considered each lung as an in-
dependent observation, thus allowing to analyse par-
ticular situations such as bilateral PT. We restricted
the analyses to cases with available dates of events
and excluded those with missing, incomplete or
doubtful dates, even if a PT was narratively reported
as occurring after AT (n = 3). By using a 30-days
interval as the period at risk for PT occurrence after
AT, we took into account the fact that PT occurrence
and diagnosis may be delayed, as previously reported
[17].
Our study has several limitations. As the study design
was a patient survey, we did not check the accuracy of
the diagnosis. However, since patients were members of
LAM associations, we assumed that LAM was the cor-
rect diagnosis in all. As study participants were lay per-
sons, one could argue that they did not have enough
knowledge to accurately fill the questionnaire. However,
participants were not a sample of the general population,
but young adults affected by a rare disease, and mem-
bers of LAM patient associations, which provide regular
educational sessions on LAM to their members. These
patients were therefore well informed of PT mecha-
nisms, symptoms, diagnosis and therapy. We recorded a
maximum of 4 AT and 4 PT episodes, which may have
led to underestimate the number of events. However,
the number of patients who experienced 4 PT on the
same side was small (n = 10), and we believe that we did
not miss an important proportion of events. Recall bias
and errors in questionnaire filling might have occurred.
However, we checked by a second questionnaire the val-
idity of the data regarding PT occurring after AT.
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Patients who replied to the survey may not be fully rep-
resentative of the whole LAM population. Furthermore,
patients who experienced symptoms during AT or feared
the occurrence of PT may have been more prone to re-
spond to the survey. The number of events was small,
and a larger sample would be required to measure more
accurately the risk of PT occurrence after AT. We
acknowledge that, even if used in one previous study on
PT and AT in BHD [18], the 30-days interval used to de-
fine the period at risk of PT after AT was arbitrary.
However, shorter intervals would have led to a reduced
number of events and an underpowered analysis,
whereas longer intervals would have obfuscated
AT-related PT among spontaneous PT. Finally, other
causes of decreased barometric pressure, such as me-
teorological changes or ascent to high altitude, were not
accounted. Despite these methodological limitations, we
believe that our approach provides a valuable new
insight in a poorly studied phenomenon.
Conclusion
The annual incidence of PT in the LAM population was
8% per year since the first symptoms and 5% per year
since LAM diagnosis, i.e. around 1000 times higher than
the risk of spontaneous PT in the general female popula-
tion. Pleurodesis after the first PT partially but signifi-
cantly reduced the risk of subsequent PT. The
probability of PT within 30 days after AT was increased
threefold as compared to periods without AT, suggesting
for the first time that AT by itself could be a risk factor
for PT occurrence in LAM. This study also illustrates
the valuable role of patient associations in research on
rare diseases.
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